Publications

Colca, J.R., McDonald, W.G., McCommis, K.S., Finck, B.N. (2017) Treating Fatty Liver Disease by Modulating Mitochondrial Pyruvate Metabolism.  Hepatology Comm. 1:193-197.  http://onlinelibrary.wiley.com/doi/10.1002/hep4.1036/epdf

McCommiss, K.S., Hodges, W.T., Brunt, E.M., Nalbantoglu, I., MDonald, W.G., Holley, C., Fujiwara, H., Schaffer, J.E., Colca, J.R., Finck, B.N. (2016) Targeting the Mitochondrial Pyruvate Carrier Attenuates Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis. Hepatology. Doi: 101002/hep.29025.  https://www.ncbi.nlm.nih.gov/pubmed/28027586

Colca, J.R. (2015) The TZD insulin sensitizer clue provides a new route into diabetes drug discovery.  Expert Opin Drug Discov. 10(12):1259-70.  https://www.ncbi.nlm.nih.gov/pubmed/26479699

McCommis, K.S., Chen, Z., Fu, X., McDonald, W.G., Colca, J.R., Kletzien, R.F., Burgess, S.C., Finck, B.N. Loss of Mitochondrial Pyruvate Carrier 2 in the Liver Leads to Defects in Gluconeogenesis and Compensation via Pyruvate-Alanine Cycling. Cell Metab. (2015); 22:682-94.  https://www.ncbi.nlm.nih.gov/pubmed/26344101

Shah R.C., Matthews D.C., Andrews R.D., Capuano A.W., Fleischman, VanderLugt J.T., Colca J.R. (2014) An Evaluation of MSDC-0160, a Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer’s Disease. Current Alzheimer Research 11:564-573.  https://www.ncbi.nlm.nih.gov/pubmed/24931567

Fukunaga T., Zou W.,  Rohatgi  N.,  Colca J.R.,  Teitelbaum, S.L. (2014) An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss. J Bone Miner Res. doi: 10.1002/jbmr.2364.  https://www.ncbi.nlm.nih.gov/pubmed/25257948

Colca, J.R., McDonald, W.G., Kletzien, R.F. (2014) Mitochondrial target of thiazolidinediones. Diabetes, Obesity, and Metabolism 16(11):1048-54.  https://www.ncbi.nlm.nih.gov/pubmed/24774061

Colca, J.R. VanderLugt, J.T., Adams, W.J., Shashlo, A., McDonald, W.G., Liang, J., Zhou R., Orloff, D.G. (2013) Clinical proof of concept with MSDC-0160, a prototype mTOT modulating insulin sensitizer. Clinical Pharmacology and Therapeutics, 93:  352-359.  https://www.ncbi.nlm.nih.gov/pubmed/23462886

Colca, J.R., McDonald, W.G., Cavey, G.S., Cole S.L., Holewa, D.D., A.S. Brightwell-Conrad, A.S., Wilson, J., Coulter, K., Kilkuskie, P., Gracheva, E., Karr, R., Wiley, S., Divakaruni, A.S., Murphy, A., Finck, B.N., Kletzien, R.F. (2013) Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)-relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS ONE 8:e61551:1-10.  https://www.ncbi.nlm.nih.gov/pubmed/23690925

Colca J.R., Tanis S.P., McDonald W.G., Kletzien R.F. (2013) Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases. Exp. Opin. Invest. Drugs 23: 1-7.  https://www.ncbi.nlm.nih.gov/pubmed/24073940

Divakaruni, A.S., Wiley, S.E., Rogers, G.W., Andreyev, A.Y., Petrosyan, S., Loviscach, M., Wall, E.A., Yadava, N., Heuck, A.P., Ferrick, D.A., Henry, R.R., McDonald, W.G., Colca, J.R., Simon, M.I., Ciaraldi, T.P., Murphy, A.N. (2013) Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. PNAS 110: 5422 – 5427.  https://www.ncbi.nlm.nih.gov/pubmed/23513224

Rohatgi, N., Aly, H., Marshall, C.A., McDonald, W.G., Kletzien, R.F., Colca, J.R., McDaniel, M.L. (2013). Novel Insulin Sensitizer Modulates Nutrient Sensitizing Pathways and Maintains b-cell Phenotype in Human Islets. PloS ONE:8 e62012: 1-13.  https://www.ncbi.nlm.nih.gov/pubmed/26479699

Chen, Z., Vigueira, P.A., Chambers, K.T., Hall, A.M., Mitra, M.S., Qi, N., McDonald, W.G., Colca, J.R., Kletzien, R.F., Finck, B.N.  (2012) Insulin Resistance and Metabolic Derangements in Obese Mice Are Ameliorated by a Novel Peroxisome Proliferator-activated Receptor-sparing Thiazolidinedione. J. Biol. Chem., 287: 23537-23548.  https://www.ncbi.nlm.nih.gov/pubmed/22621923